CNTX

Context Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website contexttherapeutics.com
Employees(FY) 9
ISIN US21077P1084

Performance

-20.49%

-20.1%

-35.57%

-18.5%

+44.25%

YTD

+73.42%

Profile

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of CNTX 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 40 suggesting a neutral stance, and a Technical Score of 25 reinforcing the overall bearish outlook. This combination signals caution for potential investors, as the prevailing trend appea...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CNTX

Stock Rank

Recent News & Updates

2024-11-06 03:06
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results(Globenewswire)
2024-10-22 19:30
Context Therapeutics to Participate in Upcoming Investor Conferences in November(Globenewswire)
2024-10-15 19:30
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting(Globenewswire)
2024-09-22 19:30
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody(Globenewswire)
2024-09-11 21:40
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?(Yahoo Finance)
2024-09-03 19:30
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors(Globenewswire)
2024-08-26 21:40
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?(Yahoo Finance)
2024-08-07 04:17
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results(Globenewswire)
2024-07-31 19:30
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations(Globenewswire)
2024-07-09 19:30
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95(Globenewswire)
2024-05-29 18:11
Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight(Investorplace)
2024-05-22 08:50
The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains(Investorplace)
2024-05-20 00:00
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice(Zacks)
2024-05-14 00:00
Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why(Zacks)
2024-05-08 11:56
CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-08 04:06
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results(Globenewswire)
2024-05-01 19:31
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76(Globenewswire)
2024-05-01 19:30
Context Therapeutics Announces $100 Million Private Placement(Globenewswire)
2024-03-31 19:30
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers(Globenewswire)
2024-03-21 01:53
CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023(Investorplace)
2024-03-20 19:43
Context Therapeutics Reports Full Year 2023 Operating and Financial Results(Globenewswire)
2023-11-09 03:15
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results(Globenewswire)
2023-10-30 21:00
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76(Globenewswire)
2023-10-24 00:30
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis(Yahoo Finance)
2023-09-26 21:00
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting(Globenewswire)
2023-08-10 02:19
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update(Yahoo Finance)
2023-08-09 04:10
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results(Yahoo Finance)
2023-07-31 19:30
Context Therapeutics to Participate in Two August 2023 Investor Conferences(Yahoo Finance)
2023-06-13 01:34
Context Therapeutics shares #ASCO23 data on CLDN-6 targeted treatments and CTIM-76 update(Yahoo Finance)
2023-06-02 20:27
Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?(Yahoo Finance)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.